We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tate & Lyle Plc | LSE:TATE | London | Ordinary Share | GB00BP92CJ43 | ORD 29 1/6P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.50 | -0.40% | 617.50 | 619.50 | 620.50 | 622.00 | 615.50 | 622.00 | 1,031,386 | 16:35:22 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Flavoring Extract,syrup, Nec | 1.85B | 190M | 0.4730 | 13.12 | 2.49B |
Date | Subject | Author | Discuss |
---|---|---|---|
26/2/2024 08:24 | Hope you’re right - been a bit disappointing here recently. Suet | suetballs | |
26/2/2024 08:00 | 613.5p, worth it for long term, imo | demo trader | |
21/2/2024 08:44 | This is what matters most IMO, outlook for the year ending 31 March 2024, EBITDA growth unchanged at 7% to 9%. so on reduced volumes pricing has driven the numbers, as volumes recover over 2024 when restocking takes place we are very well positioned.. | laurence llewelyn binliner | |
21/2/2024 07:36 | Not sure what to make of the Q3 update. No nasty surprises it seems. Suet | suetballs | |
05/2/2024 11:26 | The stagnant BB matches the share price , Q3 figures in 2 weeks , doubt will stir it up much! | wad collector | |
05/12/2023 16:20 | More multi million pound trades today | justiceforthemany | |
01/12/2023 14:54 | No BOD buying, even at these levels | essentialinvestor | |
27/11/2023 15:05 | Some huge buys today. Millions.. | justiceforthemany | |
27/11/2023 14:37 | Money moving to PFC | blackhorse23 | |
23/11/2023 17:59 | Confusingly Tate and Lyle Sugars is part of ASR group and not Tate and Lyle (after T&L sold it off in 2010). But, if you want a closer sugar tie up, the husband of the current health secretary is the MD of British Sugar (which is owned by ABF - incl. Primark!, not T&L) | pete160 | |
23/11/2023 17:38 | hxxps://www.wearetat | justiceforthemany | |
23/11/2023 16:46 | * they divested the sugar business some year go - just to clarify. | essentialinvestor | |
23/11/2023 16:45 | Decade lows. Balance sheet looks v.good P/E a very reasonable 11-12 Yet another bargain if any buyers are out there - historic BRITISH brand. | justiceforthemany | |
09/11/2023 08:29 | The outlook is cautiously positive too, looks like the share-price nadir may have passed. | wad collector | |
09/11/2023 07:35 | Nothing spectacular as expected. Div increase 14% compared to last yrs interim. Will continue to hold & add any dips under 620. | horace rawlplug | |
09/11/2023 07:17 | Good results and increased dividend . | csalvage | |
29/10/2023 08:11 | Well, as fickle as it seems, could the next 5 months turn this around. Xmas and an early Easter may well be too obvious, but then do algorithmic calculations take in Easter following Xmas so quickly? | hedgefundkick | |
25/10/2023 09:28 | Well they eradicated smallpox. And it's not a quango. They are saying with this release that stats show artificial sweeteners used alone shouldn't be used for weight control. i.e. the people who have tried to use them for weight control have failed to control their weight. My view is it's more to do with the people rather than the sweetener. Strangely, they say if you are diabetic (i.e. can't control your weight by any means in many cases) then just carry on using them. Or if the sweetener is mixed with some sugar, then keep taking it. It's only those sweetners not mixed with sugar. So simples, add a bit of sugar to a sweetener tablet and the advice is to keep taking it. It's an interim statement until they look into the link between diabetes and sweeteners. (Again, i suspect they'll find it's the people causing diabetes not the sweeteners). It's an extremely cautious bit of temporary advice. Of course, the advice may do more harm than good (if anyone follows it, which i doubt), by those having 6 spoons of sugar in their tea instead of 6 aspartame tabs, hence probably making them fatter hence more likely to become diabetic (when, if they follow the advice, they can start taking sweeteners again!). | pierre oreilly | |
25/10/2023 08:24 | The science of nutrition is fraught with difficulty ; it is hard to do a long term controlled trial, so most of the studies are observational. And thus confused by confounding variables and the dishonesty of many people's reported intakes. The WHO has taken a cautious position on sweeteners , but acknowledges that there is little differentiation between all of the different categories, so most of the data is lumped together . They acknowledge that their advice on non-sugar sweeteners is conditional and based on evidence of low certainty. The guidance recommends against using sweeteners for weight control and prevention of non-communicable diseases in non-diabetics. But that is not the same as recommending that people use sugar based sweeteners instead. I don't suppose many people view non-sugar sweeteners as harmless, but they accept that whatever risk they carry is acceptable for the benefits of taste. So I can't see that the WHO's latest guideline will make a seachange in the sweetener industry without substantially better and more specific research, and that is very difficult to achieve. | wad collector | |
19/10/2023 22:45 | wad, the fear may be further data emerges and they become less widely used, otherwise I can't add anything else. | essentialinvestor | |
19/10/2023 20:30 | I am not sure that most people take much notice of WHO dietary recommendations. Look at the queues at MacDonalds. | wad collector | |
19/10/2023 12:52 | I mentioned this previously. If you take a look at the YTD share price it corresponds to the above. | essentialinvestor | |
19/10/2023 12:33 | Good question but no obvious answer. The sector is not doing badly . | wad collector |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions